期刊文献+

染色体1p/19q杂合性缺失与少突胶质细胞肿瘤临床病理特征的关系 被引量:1

Relationship between the loss of heterozygosity on chromosome 1p/19q and clinicopathologic feature in oligodendroglial tumors
原文传递
导出
摘要 目的 探讨染色体1p/19q杂合性缺失与少突胶质细胞肿瘤临床病理特征的关系.方法 采用荧光免疫原位杂交技术检测73例少突胶质细胞肿瘤1p/19q杂合性缺失,并随访观察预后.结果 少突胶质细胞肿瘤年轻患者(< 60岁)1p/19q缺失高于老年患者(>60岁,P<0.01);好发部位(额、顶、枕叶)的少突胶质细胞肿瘤1p/19q缺失与其他部位比较差异无统计学意义(P>0.05),与性别及肿瘤级别均无明显相关(P>0.05);少突胶质细胞肿瘤患者存在1p/19q联合缺失的中位生存时间为74个月,5年总生存率为72%;仅存在1p缺失者中位生存时间为43个月,5年总生存率为29%;而不存在1p/19q缺失者中位生存时间39个月,5年总生存率为18%.1p/19q联合缺失者中位生存时间长于仅存在1p缺失组,差异有统计学意义(P<0.05);且1p/19q缺失组中位生存时间也长于1 p/19q未缺失组,差异有统计学意义(P<0.05).仅存在1p缺失组中位生存时间虽然长于不存在1p/19q缺失组,但差异无统计学意义(Pp>0.05).结论 少突胶质细胞肿瘤1p/19q缺失与患者年龄明显相关,与患者性别、肿瘤发生部位及肿瘤级别无明显相关;少突胶质细胞肿瘤中染色体1p/19q杂合性缺失对患者的化疗敏感性及预后有关,可以作为分子分型的标准. Objective To investigate the relationship between the loss of heterozygosity (LOH)on chromosome 1p/19q and clinicopathologic feature in oligodendroglial tumors.Methods The LOH on chromosome 1 p/19q was detected with fluorescence in situ hybridization in 73 patients with oligodendroglial tumors,and the prognosis was followed up.Results The positive rate of the LOH on chromosome 1p/19q in oligodendroglioma in younger patients (〈 60 years old) was higher than in older patients (〉 60 years old),(P 〈 0.01).There was no statistically significant difference in the LOH on chromosome 1 p/19q betwcen the oligodendroglial tumors at frontal lobe and other lobes (P 〉 0.05).There was no statistically significant difference in the LOH on chromosome 1p/19q in oligodendroglioma between low grade and high grade (P 〉0.05).There was no statistically significant difference in the LOH on chromosome 1p/19q in oligodendroglioma between males and females.The median survival time of patients with the LOH on chromosome 1 p/19q of oligodendroglioma was 74 months,and total 5-year survival rate was 72%.The median survival time in patients with 1 p LOH was 43 months,and the total 5-year survival rate was 29%.The median survival time of patients without 1 p/19q LOH was 39 months,and total 5-year survival rate was 18%.The median survival time of patients with 1p/19q LOH was significantly longer than that of those with 1 p LOH (P 〈 0.05).The median survival time of patients with 1 p/19q LOH was significantly longer than that of those without 1 p/19q LOH (P 〈 0.05).The median survival time of patients with 1 p LOH was longer than that in those without 1p/19q LOH,but there was no statistically significant difference (P〉0.05).Conclusion The LOH on chromosome 1 p/19q in oligodendroglioma was obviously correlated with patients' age,but not with gender,tumor location and tumor grade.There were correlations between the LOH on chromosome 1 p/19q of oligodendroglioma and chemotherapy sensibility and prognosis.The LOH on chromosome 1p/19q of oligodendroglioma can act as the classified standard of molecular subtyping.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第12期2882-2884,共3页 Chinese Journal of Experimental Surgery
基金 江西省教育厅重点资助项日(GJJ10015) 江西省科技厅支撑计划资助项目(2009BSB11206)
关键词 少突胶质细胞肿瘤 染色体 杂合性缺失 临床病理特征 Oligodendroglial tumors Chromosome Heterozygosity loss Clinicopathologic feature
  • 相关文献

参考文献19

  • 1Bourne TD,Schiff D.Update on molecular findings,management and outcome in low-grade gliomas[J].Nat Rev Neurol,2010,6(12):695-701.
  • 2Hofer S,Lassman AB.Molecular markers in gliomas:impact for the clinician[J].Target Onco1,2010,5(3):201-210.
  • 3刘朝霞,任晓辉,崔向丽,于洮,姜中利,隋大立,林松.胶质瘤1号和19号染色体多体与临床病理影像学因素的相关性[J].军医进修学院学报,2011,32(12):1211-1213. 被引量:1
  • 4Reifenberger G,Louis DN.Oligodendroglioma:toward molecular definitions in diagnostic neuron-oncology[J].J Neuropathol Exp Neurol,2003,62(2):111-126.
  • 5Smith JS,Perry A,Borell TJ,et al.Alterations of chromosome amislp and 19q as predictors of survival in oligodendrogliomas,astrocytomas,and mixed oligoastrocytomas[J].J Clin Oncol,2000,18(3):636-645.
  • 6Chinot O.Chemotherapy for the treatment of oligodendroglial tumors[J].Semin Oncol,2001,28(4 suppl 13):13-18.
  • 7Van den Bent MJ.New perspectives for the diagnosis and treatment of oligodendroglioma[J].Expcrt Rev Anticancer Ther,2001,1(3):348-356.
  • 8张淑坤,卢德宏,朴月善,蔡彦宁,徐庆中.即时荧光定量PCR微卫星分析技术检测少突胶质细胞肿瘤染色体1p/19q杂合性缺失[J].中华病理学杂志,2006,35(12):731-734. 被引量:9
  • 9何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量:10
  • 10Huang L,Jiang T,Yuan F,et al.Correlation of chromosome lp and l9q status and expression of MGMT,p53 and Ki-67 in diffuse gliomas of WHO grade Ⅱ and Ⅲ:a clinicopathological study[J].Neuropathol Appl Neurobiol,2009,35(4):367-379.

二级参考文献69

  • 1Bromberg JE, van den Bent MJ. Oligodendrogliomas: mo- lecular biology and treatment [J]. Oncologist, 2009, 14(2): 155-163.
  • 2Buckner JC, Brown PD, ONeill BP, et al. Central nervous system tumors [J]. Mayo Clin Proc, 2007, 82(10): 1271-86.
  • 3Ichimura K, Vogazianou AP, Liu L, et al. lp36 is a pre- ferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas [J]. Oncogene, 2008, 27(14): 2097-2108.
  • 4Lavon I, Zrihan D, Zelikovitch B, et al. Longitudinal assessment of genetic and epigenetic markers in oligo- dendrogliomas [J]. Clin Cancer Res, 2007, 13 (5): 1429- 1437.
  • 5Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of lp and 19q and predicts a better prognosis of patients with oligoden- droglioma [J]. Cancer Res, 2006, 66(20): 9852-9861.
  • 6McDonald JM, See SJ, Tremont IW, et al. The prognostic impact of histology and lp/19q status in anaplastic oligodendroglial tumors [J]. Cancer, 2005, 104(7): 1468- 1477.
  • 7Jaeekle KA, Ballman KV, Rao KD, et ol. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response [J]. J Clin Oncol, 2006, 24(8): 1246- 1252.
  • 8Goze C, Rigau V, Gibert L, et al. Lack of complete lp19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis [J]. J Neurooncol, 2009, 91(1): 1-5.
  • 9Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction [J]? Nat Rev Cancer, 2006, 6(2): 107-116.
  • 10Mollemann M, Wolter M, Felsberg J, et al. Frequent pro- moter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors [J]. Int J Cancer, 2005, 113 (3): 379-385.

共引文献37

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部